PT Darya-Varia Laboratoria Tbk

DVLA

ID1000117203

Pharmaceuticals

End-of-day quote INDONESIA S.E. Other stock markets 23:00:00 27/05/2024 BST			5-day change	1st Jan Change
1,540 ^IDR	+1.99%		+2.33%	-7.51%

04-29	PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-22	PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tranche Update on PT Darya-Varia Laboratoria Tbk's Equity Buyback Plan announced on June 16, 2014.

October 02, 2014

From June 13, 2014 to June 20, 2014, the company has repurchased 4,074,700 shares, representing 0.36% for IDR 8,560.94 million. With this, the company has completed the repurchase of 4,074,700 shares, representing 0.36% for IDR 8,560.94 million under the buyback announced on June 16, 2014.

Latest news about PT Darya-Varia Laboratoria Tbk

PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23	CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Half Year Ended June 30, 2023	27/07/23	CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the First Quarter Ended March 31, 2023	26/04/23	CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Nine Months Ended September 30, 2022	14/11/22	CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Half Year Ended June 30, 2022	23/08/22	CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the First Quarter Ended March 31, 2022	29/05/22	CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Full Year Ended December 31, 2021	20/04/22	CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Nine Months Ended September 30, 2021	18/11/21	CI
Pt Darya-Varia Laboratoria Tbk Reports Earnings Results for the Half Year Ended June 30, 2021	26/08/21	CI
Pt Darya-Varia Laboratoria Tbk Reports Earnings Results for the Full Year Ended December 31, 2020	23/05/21	CI
Pt Darya-Varia Laboratoria Tbk Reports Earnings Results for the Half Year Ended June 30, 2020	29/07/20	CI
PT Darya-Varia Laboratoria Tbk Launches New Variant, Natur-E White Series	12/05/20	CI
Pt Darya-Varia Laboratoria Tbk Reports Earnings Results for the Full Year Ended December 31, 2019	01/04/20	CI
Pt Darya-Varia Laboratoria Tbk Reports Earnings Results for the Nine Months Ended September 30, 2019	29/10/19	CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Half Year Ended June 30, 2019	30/07/19	CI
Pt Darya-Varia Laboratoria Tbk Reports Earnings Results for the First Quarter Ended March 31, 2019	29/04/19	CI
PT Etana Biotechnologies Indonesia announced that it has received IDR 34.302 billion in funding from PT Darya-Varia Laboratoria Tbk, Etana Biotechnologies Hong Kong Limited	20/06/18	CI
PT Etana Biotechnologies Indonesia announced that it expects to receive IDR 34.302 billion in funding from PT Darya-Varia Laboratoria Tbk, Etana Biotechnologies Hong Kong Limited	04/06/18	CI
PT Darya-Varia Laboratoria Tbk Announces New Office	01/09/16	CI
An unknown buyer acquired 0.54% stake in PT Darya-Varia Laboratoria Tbk from Blue Sphere Singapore Pte. Ltd. for $0.57 million.	25/01/16	CI
Tranche Update on PT Darya-Varia Laboratoria Tbk's Equity Buyback Plan announced on June 16, 2014.	02/10/14	CI
PT Darya-Varia Laboratoria Tbk completed the acquisition of the remaining stake in PT Pradja Pharin from Marlia Hayati Goestam.	07/07/14	CI

Chart PT Darya-Varia Laboratoria Tbk

Duration

Period

More charts

Company Profile

PT Darya-Varia Laboratoria Tbk is an Indonesia-based pharmaceutical company. Its segments include prescription drugs, consumer health products, export and toll manufacturing services and services. Its consumer health products include skin nutrition, respiratory, vitamins and daily relief. Its prescription products include Daryaven, Urdafalk and Aspilets. Through its multivitamin brands, such as Enervon-C, Enervon Active, Enervon Gold and Supertin, it helps to boost body immune and maintain health. It also provides Imunped as a supplement for kids with Zinc and vitamin C, which are essential for children. Its Forti-D 1000 IU is a health supplement (vitamin) product. Fortagyl provides prevention and treatment of amoebiasis, trichomoniasis, giardiasis and post-operation infections. It provides toll manufacturing services for both local and international principals with its two manufacturing facilities: Gunung Putri and Citeureup manufacturing facilities.

Sector

Pharmaceuticals

Calendar

21/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PT DARYA-VARIA LABORATORIA TBK	-7.51%	105M
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	354B
MERCK & CO., INC.	+15.66%	328B
ABBVIE INC.	+0.24%	277B
ASTRAZENECA PLC	+13.47%	243B
NOVARTIS AG	+7.35%	205B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+4.23%	164B
PFIZER, INC.	-1.70%	164B